Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti Angiogenesis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00879684
What this trial is testing

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsNeoplasmsCarcinoma+2 more
Pfizer 34
Not applicableStudy completedNCT00009035
What this trial is testing

Natural History of Patients With Brain and Spinal Cord Tumors

Who this might be right for
AstrocytomaOligodendrogliomaGlioblastoma+2 more
National Cancer Institute (NCI) 3,050
Early research (Phase 1)Study completedNCT00033215
What this trial is testing

S-3304 in Patients With Solid Tumors

Who this might be right for
Solid Tumors
Shionogi 32
Not applicableStudy completedNCT01404910
What this trial is testing

Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery

Who this might be right for
Preeclampsia
Massachusetts General Hospital 11
Large-scale testing (Phase 3)Study completedNCT00334282
What this trial is testing

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
GlaxoSmithKline 435
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06537505
What this trial is testing

Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Who this might be right for
Solid Tumor
Beidahuang Industry Group General Hospital 60
Testing effectiveness (Phase 2)Study completedNCT06562673
What this trial is testing

Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

Who this might be right for
OsteosarcomaBone Cancer
Shanghai 6th People's Hospital 10
Not applicableUnknownNCT04523467
What this trial is testing

Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital 320
Not applicableStudy completedNCT07375901
What this trial is testing

The Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration

Who this might be right for
AMD
The Filatov Institute of Eye Diseases and Tissue Therapy 30
Testing effectiveness (Phase 2)Study completedNCT04877821
What this trial is testing

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Who this might be right for
Triple Negative Breast Cancer
Guangdong Provincial People's Hospital 29
Early research (Phase 1)Study completedNCT01120288
What this trial is testing

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

Who this might be right for
NeoplasmsLiver Metastases
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Study completedNCT00691379
What this trial is testing

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46
Testing effectiveness (Phase 2)Study completedNCT03013335
What this trial is testing

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Who this might be right for
Metastatic Renal Cell Carcinoma
UNICANCER 730
Not applicableUnknownNCT05874115
What this trial is testing

Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
Centro di Riferimento Oncologico - Aviano 75
Testing effectiveness (Phase 2)Study completedNCT00134355
What this trial is testing

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 5
Testing effectiveness (Phase 2)Ended earlyNCT01239355
What this trial is testing

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaLocalized Non-Resectable Adult Liver Carcinoma+1 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)UnknownNCT02584478
What this trial is testing

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Who this might be right for
Endometrial CarcinomaOvarian CarcinomaFallopian Tube Carcinoma+2 more
Advenchen Laboratories, LLC 294
Early research (Phase 1)Study completedNCT01105533
What this trial is testing

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Who this might be right for
Neoplasm
Pfizer 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT06884345
What this trial is testing

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Anhui Provincial Cancer Hospital 28
Testing effectiveness (Phase 2)Ended earlyNCT00850577
What this trial is testing

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 255
Next Page